https://scholars.lib.ntu.edu.tw/handle/123456789/495024
標題: | Reply to F. de Marinis et al | 作者: | CHIH-HSIN YANG Sequist L.V. |
公開日期: | 2014 | 出版社: | American Society of Clinical Oncology | 卷: | 32 | 期: | 8 | 來源出版物: | Journal of Clinical Oncology | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899668031&doi=10.1200%2fJCO.2013.54.1904&partnerID=40&md5=1eb64750380eda952270517816a92f78 https://scholars.lib.ntu.edu.tw/handle/123456789/495024 |
ISSN: | 0732-183X | DOI: | 10.1200/JCO.2013.54.1904 | SDG/關鍵字: | afatinib; epidermal growth factor receptor; loperamide; afatinib; antineoplastic agent; epidermal growth factor receptor; quinazoline derivative; cancer chemotherapy; clinical trial (topic); diarrhea; diet; drug dose reduction; drug safety; gene mutation; human; letter; priority journal; progression free survival; quality of life; treatment duration; adenocarcinoma; female; genetics; lung adenocarcinoma; lung tumor; male; note; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Quinazolines; Receptor, Epidermal Growth Factor |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。